De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC

Summary

This study is a single-arm exploratory study conducted in LAHNSCC. Eligible patients received two cycles of pembrolizumab immunotherapy in combination with albumin-bound paclitaxel and cisplatin induction chemotherapy, followed by definitive concurrent radiochemotherapy. Three months after the completion of radiotherapy, a follow-up examination was conducted, and salvage surgery or systemic therapy was performed as necessary based on the follow-up results.

Timeline

Start

2023-10-17

Primary completion

2026-09

Completion

2027-04

Drugs

Indications